The evidence base.
Oncobiotix's approach stands on a decade of peer-reviewed science — mechanism in preclinical models, association in patients, and interventional evidence in humans. Our own founding paper is first below; the rest is a representative, non-exhaustive map of the field OBX34 builds on.
The paper OBX34 is built on.
Oncobiotix was founded on this work: the identification of hydroxyphenyl propanoates as a class of microbiome-derived metabolites that potentiate Gasdermin D in tumor-associated myeloid cells, and the demonstration that supplementing them improves response to checkpoint blockade — including in preclinical models whose microbiome has been stripped by antibiotics.
Posted 27 April 2026. A preprint has not been peer reviewed. Everything below is peer-reviewed work by others.
Preclinical mechanism
Where the field began, and where the mechanism has since gone: commensal bacteria are required for — and can enhance — the efficacy of checkpoint blockade in preclinical models, and the metabolites those bacteria produce are now being resolved as the active signal.
Human observational cohorts
The preclinical mechanism carried into patients: three back-to-back 2018 Science papers independently linked baseline gut composition to anti–PD-1 response — and flagged the antibiotic effect.
Interventional evidence — fecal microbiota transplant
The evidence that reprogramming the microbiome changes clinical outcomes: donor transplant from responders re-opened response in refractory melanoma, and the biology now replicates in the randomized era.
Antibiotics & a disrupted gut → worse outcomes
The "damage" axis and the core clinical rationale: disrupting the microbiome around checkpoint therapy — most often with antibiotics — measurably worsens response and survival, replicated across tumor types and, in pooled analysis, 41,663 patients across 123 cohorts.
Reviews & translational frameworks
Orientation and the road toward companion biomarkers — authoritative overviews of cultivating the microbiome for immunotherapy, and the signatures framework for patient stratification.
This is a curated, representative landscape of landmark work (2015–2026), not an exhaustive review, and does not imply endorsement of Oncobiotix by the cited authors. Oncobiotix's own preclinical data package is available on request.
This is the biology. OBX34 is the drug.
See how Oncobiotix turns a decade of published science into a defined, developable medicine.